Steward Partners Investment Advisory’s Quince Therapeutics QNCX Stock Holding History

Steward Partners Investment Advisory’s Portfolio QNCX Stock Details QNCX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-5	Closed	-$2K	–	3355
2022 Q2	$2K	Sell	5 -1	-17%	-$707	﹤0.01%	3035
2022 Q1	$7K	Buy	6 +3	+100%	+$4.08K	﹤0.01%	2788
2021 Q4	$6K	Hold	3	–	–	﹤0.01%	2781
2021 Q3	$46K	Hold	3	–	–	﹤0.01%	1949
2021 Q2	$27K	Hold	3	–	–	﹤0.01%	4453
2021 Q1	$18K	Hold	3	–	–	﹤0.01%	2524
2020 Q4	$14K	Buy	3 +2	+200%	+$17.7K	﹤0.01%	2188
2020 Q3	$12K	Sell	1 -1	-50%	-$9.1K	﹤0.01%	2074
2020 Q2	$22K	Buy	+2	New	+$18.3K	﹤0.01%	1739

Other funds holding QNCX

ECG

EPIQ Capital Group San Francisco, California $383M AUM 46.87% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

PHAM

Pacific Heights Asset Management San Francisco, California $2.99B AUM 52.5% 1-Year Est. Return

Steward Partners Investment Advisory's QNCX Position: Q3 2022 in Review

Steward Partners Investment Advisory sold out of Quince Therapeutics (QNCX) in Q3 2022, closing a stake of 5 shares — an estimated $2K sold.

Steward Partners Investment Advisory first reported a position in QNCX in Q2 2020 and held it in 9 quarters. The position peaked at $46K in Q3 2021. 58 funds tracked by Wall St. Rank hold QNCX as of Q3 2022.

Steward Partners Investment Advisory reported no remaining Quince Therapeutics position as of Q3 2022 after selling out during the quarter.
Steward Partners Investment Advisory sold 5 Quince Therapeutics shares in Q3 2022, an estimated $2K.
Steward Partners Investment Advisory first reported a position in Quince Therapeutics in Q2 2020 and held it in 9 quarters.
Steward Partners Investment Advisory's Quince Therapeutics position peaked at $46K in Q3 2021.
58 funds tracked by Wall St. Rank held Quince Therapeutics as of Q3 2022.

Based on Steward Partners Investment Advisory's 13F filing for Q3 2022, filed 10 Nov 2022.